Sanofi tops forecasts but Acomplia delay weighs
102028
Sanofi-Aventis  posted higher than expected fourth-quarter profits on Tuesday and predicted more growth for 2007, but a further delay in its key new anti-obesity drug Acomplia hit the shares.
208932
GlaxoSmithKline Plc's cervical cancer vaccine Cervarix faces a delay in winning approval in the United States, putting it further behind Merck & Co Inc's rival product Gardasil.
298049
The pharmaceutical company reported a 5 percent increase in fourth-quarter earnings but said growth would slow this year as generic competition picked up.
619694
ASTRAZENECAâS anti-clotting drug Exanta is unlikely to win US approval in the near future, the company said as it revealed a delay with another new drug, Galida for diabetes.
387905
The beleaguered drug giant&#39;s lowered forecast isn&#39;t as bad as Wall Street expected. But investors still await the long-term prognosis.
680868
Sanofi-Aventis's anti-obesity drug Acomplia is facing three generic competitors in India even before it has won full approval from some markets, Les Echos newspaper reported on Thursday.
140055
A look at Healthways before the third-quarter earnings report.
526924
Momenta announces a delay in the FDA review of its lead drug.
458557
An experimental drug from  Sanofi-Aventis, viewed as pivotal to the newly merged company's  future, showed good results in the largest clinical study of  the product to date.
530970
A report on consumer confidence due this morning may yet have an impact on market direction, but in early trading stocks are moving higher.
266489
A new drug from Sanofi-Aventis reduced  significantly episodes of atrial fibrillaton or irregular heart  beat in two clinical studies released on Sunday.
617822
The drug maker Sanofi-Aventis said its fourth-quarter profit fell 4.6 percent under pressure from European health care reforms and generic competition for its blockbuster medicines. It said earnings would be flat this year. The company, which is based in Paris, declined to comment on reports that it had discussed a merger with Bristol-Myers Squibb. Net profit at Sanofi-Aventis fell to 1.38 billion euros ($1.79 billion) in the fourth quarter from 1.44 billion euros a year earlier. Sales increased 5 percent, to 7.36 billion euros ($9.53 billion) from 7.01 billion euros.
667206
30/08/2004 A new miracle drug for obesity could prove central to the fortunes of manufacturer Sanofi-Aventis, a newly-merged firm, if the French company is successful in bringing it to the market.
409429
A new drug from Sanofi-Aventis reduced significantly episodes of atrial fibrillaton or irregular heart beat in two clinical studies released on Sunday.
599854
LONDON (CBS.MW) -- Newly merged French pharmaceutical Sanofi-Aventis (SNY) (FR:012057) on Tuesday said it can confirm the accretive impact of the merger on 2004 proforma net income after Sanofi-Synthelabo posted a 20.
365874
Sanofi&#39;s Acomplia lowers cholesterol, trims waistlines, and blocks brain receptors associated with overeating. On the market by 2006?
527030
Drugmaker Merck & Co. Inc.   boosted its 2007 earnings forecast on Wednesday, citing  higher-than-expected sales of multiple products, including its  cancer vaccine Gardasil and diabetes drug Januvia.